Bone XXXX in @entity5 : clinical features, imaging characteristics, and markers of bone metabolism.

@entity1 @entity5 @entity79 @entity4303 @entity3 @entity158
The purpose of this study was to describe the clinical presentation of bone @entity3 in @entity1 with @entity5 and to determine the diagnostic value of imaging techniques and markers of bone metabolism. METHODS: This retrospective study was performed on the entire group of @entity1 with @entity5 treated in our hospital from January 1992 to May 1999. Only @entity1 with metastasized @entity5 were included. RESULTS: Eleven of 90 @entity1 (12%) (95% confidence interval [CI], 5%-19%) with a metastasized @entity5 had symptomatic bone @entity3 . All bone @entity3 occurred in 55 @entity1 with @entity4303 (20%; 95% CI, 9%-31%). Plain radiography had a sensitivity of 44% (95% CI, 12%-76%); MRI, 100% (95% CI, 61%-100%); bone scintigraphy, 90% (95% CI, 72%-100%); and octreotide scintigraphy, 60% (95% CI, 35%-93%). In 9 @entity1 , both octreotide scintigraphy and bone scintigraphy were performed. Of 45 @entity79 , 22 (49%) were visualized by both modalities, 13 (29%) were visualized with octreotide scintigraphy but not with bone scintigraphy, and 10 (22%) were visualized with bone scintigraphy but not with octreotide scintigraphy. In 2 @entity1 , octreotide scintigraphy and bone scintigraphy provided complementary results. Markers of bone metabolism could not discriminate @entity4303 @entity1 from those without bone @entity3 . The markers of bone metabolism did not reflect the osteolytic or osteoblastic appearance of @entity3 . CONCLUSION: @entity158 is the principal symptom of bone @entity3 in @entity1 with @entity5 . Plain radiography and markers of bone metabolism do not contribute to the diagnosis of bone @entity3 . MRI has a high sensitivity for bone @entity3 . Both bone scintigraphy and octreotide scintigraphy have acceptable sensitivity and can provide complementary results.
